Evidence map›Paper›PMID 38377890›Full record

ArticleBioelectrochemistry (Amsterdam, Netherlands)2024

Electro-antibacterial therapy (EAT) to enhance intracellular bacteria clearance in pancreatic cancer cells.

Josie L Duncan, Raffae N Ahmad, Hunter Danesi, Daniel J Slade, Rafael V Davalos, Scott S Verbridge

Open access · greenAbstract read
In one paragraph

Article in Bioelectrochemistry (Amsterdam, Netherlands), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Josie L DuncanDepartment of Mechanical Engineering, Virginia Tech, Blacksburg, VA, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Tech - Emory University, Atlanta, GA, USA.
Raffae N AhmadVirginia Tech - Wake Forest University School of Biomedical Engineering and Sciences, Blacksburg, VA, USA.
Hunter DanesiVirginia Tech - Wake Forest University School of Biomedical Engineering and Sciences, Blacksburg, VA, USA.
Daniel J SladeDepartment of Biochemistry, Virginia Tech, Blacksburg, VA, USA.
Rafael V DavalosDepartment of Mechanical Engineering, Virginia Tech, Blacksburg, VA, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Tech - Emory University, Atlanta, GA, USA; Virginia Tech - Wake Forest University School of Biomedical Engineering and Sciences, Blacksburg, VA, USA. Electronic address: rafael.davalos@bme.gatech.edu.
Scott S VerbridgeVirginia Tech - Wake Forest University School of Biomedical Engineering and Sciences, Blacksburg, VA, USA.
Virginia Tech - Wake Forest University School of Biomedical Engineering & Sciences · USVirginia Tech · USThe Wallace H. Coulter Department of Biomedical Engineering · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
Sub-component for Institution # 16-01848 Novel moleculary targeted therapy of GBMP01CA207206 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DEBINSKI, WALDEMAR · 2017 to 2021
$9.0M
Consumer-based meditation app, Calm, for treatment of sleep disturbance in hematological cancer patientsR01CA262041 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Jennifer Lynne Huberty, Ruben A. Mesa · 2022 to 2026
$2.8M
Multi-receptor Targeting of GlioblastomaR01CA256285 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Waldemar Debinski · 2021 to 2026
$2.8M
Optimization of High Frequency Irreversible Electroporation (H-FIRE) for tumor ablation and immune system activation in pancreatic cancer applicationsR01CA274439 · NCI · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI Irving C Allen · 2023 to 2026
$2.1M
NCI NIH HHS P01 CA207206NCI NIH HHS P30 CA012197NCI NIH HHS R01 CA256285NCI NIH HHS R01 CA262041NCI NIH HHS R01 CA274439
6 · The paper itself

Abstract

Intratumoral bacteria have been implicated in driving tumor progression, yet effective treatments to modulate the tumor microbiome remain limited. In this study, we investigate the use of electroporation in combination with metronidazole to enhance the clearance of intracellular Fusobacterium nucleatum within pancreatic cancer cells. We explore various parameters, including electric field strength, pulse width, and pulse number to assess the permeability of pancreatic cancer cells infected with F. nucleatum, compared to non-infected cells of the same type. We subsequently quantify the clearance of intracellular bacteria when these pulsing schemes are applied to a suspension of infected pancreatic cancer cells in the presence of metronidazole. Our results reveal distinct differences in cell permeability between infected and non-infected cells, identifying a unique biophysical marker for host cells infected with F. nucleatum. We demonstrate that the combinatorial use of electroporation and metronidazole significantly enhances the delivery of metronidazole into host cells, leading to more effective clearance of intracellular F. nucleatum compared to independent treatments; we term this novel approach Electro-Antibacterial Therapy (EAT). EAT holds promise as an innovative strategy for addressing intratumoral bacteria in pancreatic cancer, other malignancies, and potentially treatment-resistant infections, offering new avenues for therapeutic intervention.

Indexed as

MetronidazolePancreatic NeoplasmsAnti-Bacterial AgentsFusobacterium nucleatumHumansAnti-Bacterial AgentsMetronidazoleAntibioticBacteriaElectroporationFusobacteriumPulsed Electric FieldsTumor Microbiome

Identifiers

PMID38377890
PMCPMC11648442
OpenAlexW4391850490

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.